Alkermes Plc
A biopharmaceutical company that develops and sells medicines for central nervous system and addiction disorders, including Aristada for schizophrenia and Vivitrol for alcohol and opioid dependence. The name Alkermes comes from the alchemical word for a red dye made from insects, nodding to the firm's roots in drug-delivery technology. Founded in 1987 and headquartered in Dublin, it grew through the merger of two drug-delivery pioneers and now lists its shares on Wall Street.
Granted 1.29M · Sold 347.3K
Granted 202.1K · Sold 100.0K
Granted 318.8K · Sold 50.0K
Granted 255.5K · Sold 10.2K
Granted 158.7K
Granted 144.4K · Sold 111.2K
Granted 239.1K · Sold 62.9K
Granted 35.3K · Bought 35.0K
Granted 896.9K · Sold 698.5K
Granted 13.2K
Granted 13.2K
Granted 49.4K
Granted 33.8K · Bought 427
Granted 39.4K
Granted 53.6K · Sold 10.8K
Granted 33.2K
Granted 54.8K · Sold 41.3K
Granted 31.6K
Granted 36.4K · Sold 2.0K
Granted 5.6K
Granted 24.0K
Granted 45.8K · Sold 32.7K
Granted 5.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Pops Richard FDirector and CEO, Alkermes plc, Director · 21 transactions | +81.8% | 1.44M | 1.29M | — | 347.3K |
| Landine Michael JSVP, Corp Dev., Alkermes, Inc. · 36 transactions | +30% | 281.7Kas of Feb 2024 | 202.1K | — | 100.0K |
| Jackson Blair CurtisEVP, Chief Operating Officer · 52 transactions | +135.1% | 241.3K | 318.8K | — | 50.0K |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. · 61 transactions | +159.1% | 229.5K | 255.5K | — | 10.2K |
| Brown Iain MichaelSVP, Chief Financial Officer · 40 transactions | +78.6% | 148.2Kas of Feb 2025 | 158.7K | — | — |
| Cooke ShaneDirector · 23 transactions | +49.3% | 135.9K | 144.4K | — | 111.2K |
| Nichols Christian ToddSVP, Chief Commercial Officer · 56 transactions | +1368.7% | 109.8K | 239.1K | — | 62.9K |
| Daglio David Angelo Jr.Director · 14 transactions | — | 109.2Kas of Jul 2024 | 35.3K | 35.0K | — |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer · 96 transactions | — | 86.4K | 896.9K | — | 698.5K |
| Anstice David WDirector · 3 transactions | -8.8% | 84.9Kas of Jun 2022 | 13.2K | — | — |
| Dixon Wendy LDirector · 3 transactions | -19.9% | 53.1Kas of Jun 2022 | 13.2K | — | — |
| McKeon Brian PDirector · 17 transactions | — | 48.5K | 49.4K | — | — |
| snyderman nancy lynn MDDirector · 11 transactions | — | 36.2K | 33.8K | 427 | — |
| Wilson Frank AndersDirector · 12 transactions | +485.7% | 35.8K | 39.4K | — | — |
| Laurencin Cato TDirector · 24 transactions | — | 33.8K | 53.6K | — | 10.8K |
| Gaynor RichardDirector · 10 transactions | +440.8% | 33.0Kas of May 2025 | 33.2K | — | — |
| Wysenski NancyDirector · 7 transactions | +82.2% | 31.6Kas of Jul 2023 | 54.8K | — | 41.3K |
| Alva Emily PetersonDirector · 14 transactions | +1554.5% | 27.3Kas of Jun 2024 | 31.6K | — | — |
| Wright Christopher IDirector · 17 transactions | — | 25.7K | 36.4K | — | 2.0K |
| Nancy J. WysenskiDirector · 2 transactions | — | 21.5Kas of Dec 2021 | 5.6K | — | — |
| Lurker NancyDirector · 10 transactions | — | 19.7K | 24.0K | — | — |
| Parisi Samuel JosephVP, Finance (Interim PAO) · 32 transactions | — | 11.1K | 45.8K | — | 32.7K |
| Nancy SnydermanDirector · 2 transactions | — | 10.3Kas of Dec 2021 | 5.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.43M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.